Reduced insulin sensitivity as a marker for acute mountain sickness? High Alt Med Biol 14:240-250, 2013-Reduced insulin sensitivity might increase the susceptibility to acute mountain sickness (AMS). The diabetogenic side effects of dexamethasone should therefore be considered for AMS treatment. To examine whether reduced insulin sensitivity is predictive of AMS and how it is affected by dexamethasone at high altitude, we analyzed endocrine and metabolic parameters obtained from healthy mountaineers in Zurich (LA; 490 m), and 2 and 4 days after fast ascent to the Capanna Regina Margherita (HA2, HA4; 4559 m). 14 of 25 participants developed AMS and were treated with dexamethasone starting in the evening of HA2. Before and after ingestion of an 1800 kJ meal, plasma was analyzed for erythropoietin (EPO) and cholecystokinin (CCK). Insulin sensitivity (HOMA-S) and beta cell activity were calculated. HOMA-S (p<0.01) and EPO levels (p<0.05) were lower in Zurich in the group developing AMS and given dexamethasone, i.e., before treatment and exposure to hypoxia. CCK was lower (p<0.01) and glucose and insulin were higher on HA4 in the dexamethasone group compared to the untreated group. Individuals with low baseline insulin sensitivity and low baseline EPO levels were more susceptible to AMS. Reduced CCK may contribute to the beneficial effect of dexamethasone on high altitude anorexia. However, reduced insulin sensitivity questions the widespread use of dexamethasone to prevent/treat AMS.
Introduction
More and more people living at or near sea level spend their spare time with activities such as hiking, skiing or climbing at higher altitude (> 2500m above sea level). The numbers of patients with metabolic syndrome, decreased insulin sensitivity or manifest diabetes increase worldwide and antidiabetic treatments have improved in recent years. As a result more patients with metabolic problems expose themselves to hypoxic conditions and may therefore want to benefit from prophylactic treatments, including dexamethasone. Dexamethasone is often used by mountaineers to prevent or treat acute mountain sickness (AMS) (14, 21, 27) .
AMS has an incidence of 15-80% depending on individual susceptibility, acclimatization, speed of ascent and maximum height reached above 2500m (13, 20, 32, 33) . Most common symptoms of AMS are headache, insomnia, fatigue, dizziness, breathlessness, anorexia and nausea (13, 19, 46, 53) .
The underlying molecular mechanisms for dexamethasone-mediated improvement of mountaineers suffering from AMS are complex and only partly understood. This is due to the fact that the primary cause of AMS is still not well known. Because hypoxia-induced systemic inflammation may play a role in the development of AMS (15, 22, 23) , the anti-inflammatory and immunosuppressant action of dexamethasone could at least partly be responsible for dexamethasone's beneficial effects in AMS.
Further, dexamethasone may modulate the release and action of gastrointestinal hormones that control food intake. Cholecystokinin (CCK), that has been shown to be increased in plasma at high altitude, may play a role in the development of AMScaused anorexia (4) . CCK is also known to be decreased by dexamethasone in cell cultures and in rats in-vivo (41) .
Dexamethasone, however, has a wide range of undesired side effects. In addition to its immunosuppressant impact that potentially increases the risk of infections and impaired wound healing, glucocorticoids have catabolic and diabetogenic effects on fat and carbohydrate metabolism (25, 48, 50) . Unfortunately for diabetics the risk of side effects of dexamethasone treatment is even higher than for healthy subjects because high altitude hypoxia itself may lead to changes in glucose homeostasis (17, 24) . This may result in changed insulin requirements and, eventually, in a deterioration of their metabolic disorders. Therefore, as a primary endpoint we investigated potential metabolic differences in patients with AMS in particular concerning insulin sensitivity, metabolites, glucose metabolism and gastrointestinal hormones. All these data were analyzed retrospectively depending on whether individuals required dexamethasone or not.
Second, we also attempted to estimate the effect of the dexamethasone treatment in a subgroup of participants.
Methods

Subjects
Twenty-five healthy and experienced mountaineers (15 male; 22-60 years) were recruited by adverts in mountain journals. As we were interested in AMS and therefore avoided acclimatization, volunteers were not allowed to stay more than 3 nights above 2500m one month prior to the fast ascent. Exclusion criteria were chronic diseases, regular medication, history of transplantation, clinically significant heart valve diseases and congenital heart or lung disease. Most volunteers had a body mass index (BMI) between 18 and 25 kg/m 2 , but two persons with a BMI slightly above 25 and one with a BMI of 31 were also included. Participants had to show normal eating behavior and were not allowed to require special diets. Eight subjects were known to have experienced high altitude pulmonary edema (HAPE) in past ascents to altitude. The Ethics Committee of the Canton of Zurich approved the study (EK-1677) that conformed to the declaration of Helsinki.
Study procedure and power calculation
We performed a power calculation to assess the sample size for the endpoint detection of a significant effect of dexamethasone on postprandial glucose concentrations. These calculations were based on a recent study by Abdelmannan et al. (1) . Those authors tested different doses of dexamethasone on postprandial glucose concentrations in healthy volunteers after a 75g oral glucose tolerance test (OGTT) and measured an increase of blood glucose concentrations from 127 ± 7.1 mg/dL to 176 ± 19 mg/dL after a single dose of 8mg dexamethasone given 24h before the following OGTT. The carbohydrate amount given in the present study and the single dose treatment with dexamethasone were comparable to the experimental high altitude were done ( Fig. 1) .
AMS assessment and medication
Occurrence of AMS was assessed using the Lake Louise Score (LLS>5) and through medical examination by experienced physicians. This study was not designed to assess the effects of dexamethasone on high altitude physiology in a randomized double blind placebo controlled fashion. Therefore for safety reasons only subjects with high HAPE susceptibility, a LLS greater 5 in the morning or evening of MG2 or necessity identified by medical examination were treated with 2 x 8 mg/day dexamethasone (9-fluor-16a-methylprednisolone, Dexamethasone Galepharm, 4 mg, Galepharm AG, 8700 Kuesnacht, Switzerland) starting on the evening of MG2, i.e., after the last blood sample had been taken on that day. One person had to be treated with dexamethasone already earlier on Day 2 so that this subject was excluded from the analysis. Due to the occurrence of AMS, 14 subjects had to be treated with dexamethasone (DEX) and 11 served as untreated controls (CON).
Study design and sample processing
Blood gas analysis was done in blood taken from the arteria radialis using an ABL 5 blood gas analyzer (Radiometer, Copenhagen and between an additional muffin preload and ad libitum dinner at 07:00 pm of each test day. For dinner, subjects were offered pasta, bolognese sauce, grated parmesan cheese and two sorts of biscuits. They were free to choose what and how much of the different foods they wanted to eat; all food consumed was weighed on a kitchen scale to the nearest gram, and energy intake was calculated. EDTA-plasma samples were kept frozen in liquid nitrogen or stored in -80°C for later analysis.
Plasma analysis
Inflammation markers
Cortisol was determined by electrochemiluminescence (Elecsys® Cortisol, Roche, Switzerland). Interleukin-6 (IL-6) and tumor necrosis factor-(TNF-) were measured using the Milliplex® MAP Human Cytokine/Chemokine Assay (Millipore).
Erythropoietin (EPO) was determined with the Human Erythropoietin Immunoassay
(Quantikine, IVD, R&D Systems, Minneapolis, USA).
Gastrointestinal hormones
The Milliplex® MAP Kit Human Endocrine (Millipore, Billerica, MA, USA) was used for amylin. Cholecystokinin (CCK-8; active) was measured using Radioimmunoassay Kits (Eurodiagnostica, Burgdorf, Switzerland) by Prof. Christoph Beglinger, University
Hospital Basel, Switzerland.
Glucose homeostasis
Glucose was measured by an enzymatic UV-Test with a Cobas Mira analyzer (Roche, Switzerland) and insulin by an ultra-sensitive Human Insulin RIA Kit (Millipore).
Calculations
Homeostasis model assessment (insulin sensitivity: HOMA S=(glucose*insulin)/22.5); beta cell activity: HOMA B=(20*insulin)/(glucose-3.5)), fasting glucose to insulin ratio (G:I) and quantitative insulin sensitivity check index
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Statistics
Statistical analysis was performed with Graphpad Software ( 
Results
Baseline characteristics
No significant differences were found between the dexamethasone-treated (DEX) and untreated groups (CON) in BMI, body weight, age, gender and in systolic, diastolic blood pressure and peripheral oxygen saturation on any test day (Table 1) .
Eight out of the 25 subjects were known to have suffered from HAPE before.
Hypoxia and clinical high altitude illness
Both groups decreased their arterial PO 2 
Assessment of insulin sensitivity
Inflammation markers and cortisol
Endogenous cortisol was measured as an internal treatment control standard in all individuals before and after medication with dexamethasone ( Fig. 2B ). As expected, endogenous cortisol was markedly lower after treatment (MG4DEX vs. MG4CON p < 0.001). Retrospective analysis indicated, however, that endogenous cortisol did not differ between groups in ZH or at MG2; in other words, endogenous cortisol was only suppressed in dexamethasone-treated participants. Based on similar cortisol levels on MG2 and ZH in both groups, the ascent on Days 0 and 1 had no influence on MG2.
Plasma IL-6 concentrations increased in both groups on MG2 compared to ZH (CON p < 0.05, DEX p < 0.01). IL-6 tended to be lower on MG4 than on MG2, but this difference was only significant in the control group (p < 0.05) and not in the dexamethasone-treated group (MG2DEX vs. MG4DEX, p = 0.07) (Fig. 2C) .
Plasma TNF-levels were lower in MG4DEX than in MG4CON (p < 0.05) (Fig. 2D) .
CCK, Amylin
Plasma levels of amylin did not differ at individual time points across groups, i.e.
there was no effect of either hypoxia or dexamethasone treatment. Amylin and CCK increased as expected after the muffin test meal in both groups and on all days. (Fig   3 C) Interestingly, CCK levels were lower in MG4DEX compared to MG4CON 30 min (p < 0.05) and 60 min (p < 0.01) after the test meal (Fig. 3C) Amylin had a greater AUC at MG2 in CON 30 and 60 min after the muffin test meal (p < 0.05). Ninety to 240 min after the muffin the AUC of amylin was greater in CON at MG2 than on ZH (p < 0.001) (data not shown).
Similarly, we also measured PYY and gastrin over the course of the study but did not detect any differences among groups (data not shown).
Caloric intake ad libitum dinner
Energy intake (kcal) during the ad libitum dinner was lower in DEX on all three days (p < 0.05) and was decreased in both groups on MG2 compared to ZH (ZHCON vs.
MG2CON p < 0.01; ZHDEX vs. MG2DEX p < 0.05). Energy intake returned to nearly baseline levels on MG4 (MG2CON vs. MG4CON p < 0.05; MG2DEX vs. MG4DEX p < 0.01) ( Fig. 5 ).
Taken together, our findings indicate that baseline insulin sensitivity and baseline
EPO levels were lower in individuals at risk of AMS; these individuals required dexamethasone treatment in the evening of MG2 because of the development of AMS.
Discussion
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The exact causes and mechanisms of AMS remain unknown. Here we intended primarily to study specifically the effects of AMS on pre-and postprandial metabolism of a caloric solid meal. Second we were interested in side effects of dexamethasone treatment on metabolism in AMS prone patients when exposed to high altitudeinduced hypoxia. Our results did not only confirm the expected effect of dexamethasone on glucose homeostasis but also revealed differences between the two groups in plasma EPO levels and insulin sensitivity already at baseline in Zurich, i.e., at low altitude and before treatment with dexamethasone.
The clinical appearance of AMS, as reflected by the Lake Louise Score (LLS), was induced by the fast ascent to high altitude with an increase on MG2 and a decrease due to acclimatization on MG4 in both groups as expected (20, 26) . The prevalence of 57% of AMS in our subjects lies within the upper range of the data reported by other groups that found a prevalence of 30-60% at altitudes between 4243m and 5671m (5, 20, 32, 54) . This may be due to the fast ascent in our study and to the study design that included eight subjects with known HAPE susceptibility. The decrease in LLS on MG4 after dexamethasone clearly shows the effective improvement in well-being of the subjects who suffered from AMS but were successfully treated with dexamethasone, as it has been reported previously (49) .
Endogenous cortisol was measured and analyzed to proof dexamethasone's efficacy. The suppressive effect of dexamethasone on endogenous cortisol production was as expected (9, 38) , i.e., the dexamethasone-treated group showed a marked decrease in the plasma levels of endogenous cortisol at MG4. Hence, the medication of the individuals suffering from AMS was considered successful.
Cytokines
Consistent with other studies, the plasma concentration of IL-6 -but not of the other cytokines -increased due to exposure to high altitude hypoxia. (15, 23) . Plasma IL-6
and TNF-decreased in the dexamethasone-treated group on MG4, an expected observation due to the anti-inflammatory effect of dexamethasone.
EPO
Erythropoietin expression is up-regulated by hypoxia (8) . As expected, plasma EPO levels therefore increased on MG2 after the fast ascent. Endogenous EPO has a relatively short plasma half-life of 6-9 hours (8) . Our results therefore indicate that the EPO production was still higher on MG4 compared to ZH but lower compared to MG2. The significantly lower EPO plasma level in the dexamethasone-treated group on MG4 can be explained by the effect of dexamethasone on gene transcription of cytokines via the glucocorticoid receptor (3, 39, 47) . Hypoxia inducible factor (HIF) enhances EPO gene transcription in response to hypoxia (51) , and Gaber et al.
showed in cultured cells that dexamethasone suppresses the expression of HIF (12).
Unfortunately this effect interferes with the acclimatization to high altitude hypoxia and, hence, contributes to the necessity to descend in case of AMS despite medication with dexamethasone. Further possible influences on plasma EPO levels such as EPO clearance from blood, have not well been investigated yet.
In apparent contrast to our study Pavlicek et al. reported no difference in baseline levels but a significantly higher EPO plasma level in HAPE susceptible subjects at high altitude (40) . Of note, one of the inclusion criteria for our study was, that the subjects were not allowed to spend more than 3 nights at 2500 m or higher one month prior to the study, but we did not completely exclude activities at altitude.
Altitude activities prior to the study and a better general state of physical fitness may have lead to the slightly but significantly higher EPO levels in ZH in the group that did not suffer from AMS (11) . However, another study (45) , which also included some of the subjects who participated in our experiments, found that VO 2max as parameter for aerobic capacity did not differ between HAPE susceptible and control subjects Hence, our results do not clearly indicate, whether there is a direct connection between plasma EPO levels at near sea level and susceptibility to AMS.
Glucose metabolism
Glucose metabolism was affected by dexamethasone on MG4 as expected.
Dexamethasone has been shown to increase glucose levels in other studies [e.g.
(35)]. We could not confirm, however, the increased glucose levels due to hypoxia or AMS itself reported by Larsen et al. (24) . Glucocorticoids affect glucose metabolism in several ways, they impair insulin dependent glucose uptake in the periphery and enhance gluconeogenesis in the liver (42, 43) .
Our data show that glucose and insulin levels increased and, hence, insulin sensitivity decreased after dexamethasone treatment on MG4, which was expected (1) . No significant changes due to hypoxia could be seen on MG2. Surprisingly, however, we found a lower insulin sensitivity in Zurich at baseline -which has to be Insulin sensitivity and AMS 13 clearly differentiated from diagnosed diabetes -in the subjects that later suffered from AMS and had to be treated with dexamethasone. This may be an indication of higher susceptibility of those individuals for AMS. We did not evaluate the subjects with respect to any hereditary predisposition for diabetes. Of note Henriksen et al showed that dexamethasone differentially alters muscle glucose metabolism of normoglycemic relatives of type 2 diabetic patients (17) . The lower plasma EPO levels in the dexamethasone-treated group already at baseline may also contribute to reduced insulin sensitivity because it has been shown that EPO improves glucose tolerance in mice by changing muscle metabolism (10, 22, 32) , and because EPO treatment of anemia in uremic patients improved insulin resistance and alleviated hyperinsulinemia (34).
Insulin sensitivity is impaired in patients with metabolic syndrome, but other symptoms such as increased blood pressure or higher BMI did not appear to be prevalent in our subjects (44). Although they did not yet show any obvious symptoms of diabetes or even overt changes in blood glucose levels, people predisposed for diabetes may have more difficulties to handle those side effects of dexamethasone because they aggravate their insulin resistance, that might have been undetected before. Therefore we analyzed insulin sensitivity by different models using fasting insulin and glucose levels, but all yielded consistent findings. We did not perform hyperinsulinemic-euglycemic clamps or oral glucose tolerance tests in our study.
Another possible indicator for assessing the blood glucose concentration over a longer period of time is glycated hemoglobin (HbA1c) (6, 16) . Nevertheless, we are convinced that the calculations of HOMA, QUICKI, glucose to insulin ratio combined with the values of fasting insulin are helpful and reliable indices to assess insulin resistance (18, 36, 37).
Hormones
Plasma CCK levels of MG4CON tended to be higher at one time point (30 min postprandially) compared to ZH and MG2, but this difference did not reach statistical significance. We could therefore not confirm the increase in resting plasma CCK that (41) . Therefore, the decrease in CCK may play a role in the improvement of AMS-associated anorexia after dexamethasone treatment.
Although we found no significant difference at single time points in amylin plasma levels that would implicate an effect of hypoxia or dexamethasone, we observed significant differences in the postprandial AUC. The AUC revealed that amylin increased more in MG2CON compared to MG2DEX at the time points 30 and 60 min and compared to ZHCON for the time points 90, 120, 180 and 240 min. Therefore the food intake induced amylin response seems to be different in subjects at high altitude compared to sea level and compared to subjects suffering from AMS. This needs to be further investigated but at least our data suggest that dexamethasone has no effect on amylin plasma levels.
Caloric intake
The overall effect of hypoxia on eating, in particular the significant decrease of caloric intake during the ad libitum dinner in both groups on MG2 confirms the results of earlier studies (28, 52). The increase in caloric intake back to nearly baseline (ZH) levels in both groups on MG4 was probably due to acclimatization and the dexamethasone treatment in the DEX group (7) . Subjects at risk for AMS (DEX) ate less than the control group on all three test days. As we did not measure hormone levels and metabolites during and after the ad libitum dinner, potential mechanisms need to be tested in future studies. For detailed analysis of caloric intake in our test subjects please see Aeberli et al. (2) .
Finally, some limitations of our study need to be mentioned. First, medication was not blinded and we had no placebo control group included due to the primary endpoint of this large-scale study. In other words, any individual who required dexamethasone treatment due to medical condition and development of AMS received the drug. The other individuals remained untreated. Nonetheless, we believe that the main conclusion of our study, i.e., that low insulin sensitivity may predispose for AMS when exposed to hypoxia, is interesting and remains valid. As the data were analyzed retrospectively, we did not carry out oral glucose tolerance tests or hyperinsulinemiceuglycemic clamps that would have allowed for stronger conclusions concerning the state of glucose metabolism. Second, due to some technical difficulties in blood Insulin sensitivity and AMS 15 sampling under field conditions and analysis, the group size (n) for some parameters is rather small.
To summarize, our results provide evidence indicating that dexamethasone in the treatment of AMS has not only positive effects on inflammation and altitude anorexia, but also carries the risk of a potentially dangerous influence on glucose metabolism, in particular as our data indicate that people with decreased insulin sensitivity may be more susceptible to AMS. Finally, this study emphasizes a clear need for further investigation and reminds the reader that dexamethasone is a potent drug but, due to the numerous possible side effects, also potentially dangerous, when taken at high altitude. 
